<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">32964520</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1530-6860</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title>
                <ISOAbbreviation>FASEB J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Relationship between GFR, intact PTH, oxidized PTH, non-oxidized PTH as well as FGF23 in patients with CKD.</ArticleTitle>
            <Pagination>
                <MedlinePgn>15269-15281</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1096/fj.202000596R</ELocationID>
            <Abstract>
                <AbstractText>Fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH) are regulators of renal phosphate excretion and vitamin D metabolism. In chronic kidney disease (CKD), circulating FGF23 and PTH concentrations progressively increase as renal function declines. Oxidation of PTH at two methionine residues (positions 8 and 18) causes a loss of function. The impact of n-oxPTH and oxPTH on FGF23 synthesis, however, and how n-oxPTH and oxPTH concentrations are affected by CKD, is yet unknown. The effects of oxidized and non-oxidized PTH 1-34 on Fgf23 gene expression were analyzed in UMR106 osteoblast-like cells. Furthermore, we investigated the relationship between n-oxPTH and oxPTH, respectively, with FGF23 in two independent patients' cohorts (620 children with CKD and 600 kidney transplant recipients). While n-oxPTH stimulated Fgf23 mRNA synthesis in vitro, oxidation of PTH in particular at Met8 led to a markedly weaker stimulation of Fgf23. The effect was even stronger when both Met8 and Met18 were oxidized. In both clinical cohorts, n-oxPTH-but not oxPTH-was significantly associated with FGF23 concentrations, independent of known confounding factors. Moreover, with progressive deterioration of kidney function, intact PTH (iPTH) and oxPTH increased substantially, whereas n-oxPTH increased only moderately. In conclusion, n-oxPTH, but not oxPTH, stimulates Fgf23 gene expression. The increase in PTH with decreasing GFR is mainly due to an increase in oxPTH in more advanced stages of CKD.</AbstractText>
                <CopyrightInformation>Â© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zeng</LastName>
                    <ForeName>Shufei</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Nephrology, CharitÃ©-UniversitÃ¤tsmedizin Berlin, Berlin, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Querfeld</LastName>
                    <ForeName>Uwe</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology, Nephrology and Metabolic Diseases, Department of Pediatrics, CharitÃ©-UniversitÃ¤tsmedizin Berlin, Berlin, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feger</LastName>
                    <ForeName>Martina</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology, University of Hohenheim, Stuttgart, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haffner</LastName>
                    <ForeName>Dieter</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatric Kidney, Liver and Metabolic Diseases, Pediatric Research Center, Hannover Medical School, Hannover, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hasan</LastName>
                    <ForeName>Ahmed A</ForeName>
                    <Initials>AA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chu</LastName>
                    <ForeName>Chang</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Nephrology, CharitÃ©-UniversitÃ¤tsmedizin Berlin, Berlin, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Slowinski</LastName>
                    <ForeName>Torsten</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nephrology, CharitÃ©-UniversitÃ¤tsmedizin Berlin, Berlin, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bernd Dschietzig</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, CharitÃ©-UniversitÃ¤tsmedizin Berlin, Berlin, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>SchÃ¤fer</LastName>
                    <ForeName>Franz</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Pediatrics and Adolescent Medicine, University of Heidelberg, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xiong</LastName>
                    <ForeName>Yingquan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Bingbing</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Physiology, University of TÃ¼bingen, TÃ¼bingen, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rausch</LastName>
                    <ForeName>Steffen</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology, University of Hohenheim, Stuttgart, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Horvathova</LastName>
                    <ForeName>Katarina</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biomedica Slovakia s.r.o., Bratislava, Slovakia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lang</LastName>
                    <ForeName>Florian</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karl KrÃ¤mer</LastName>
                    <ForeName>Bernhard</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>FÃ¶ller</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology, University of Hohenheim, Stuttgart, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hocher</LastName>
                    <ForeName>Berthold</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Medical Diagnostics, IMD, Berlin, , Berlin, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>201808080172</GrantID>
                    <Agency>China Scholarship Council (CSC)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>201706780005</GrantID>
                    <Agency>China Scholarship Council (CSC)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>201806780037</GrantID>
                    <Agency>China Scholarship Council (CSC)</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>FASEB J</MedlineTA>
            <NlmUniqueID>8804484</NlmUniqueID>
            <ISSNLinking>0892-6638</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CKD</Keyword>
            <Keyword MajorTopicYN="N">FGF23</Keyword>
            <Keyword MajorTopicYN="N">GFR</Keyword>
            <Keyword MajorTopicYN="N">PTH</Keyword>
            <Keyword MajorTopicYN="N">non-oxidized</Keyword>
            <Keyword MajorTopicYN="N">oxidized</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>03</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>9</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>9</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>9</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>40</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">32964520</ArticleId>
            <ArticleId IdType="doi">10.1096/fj.202000596R</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Title>REFERENCES</Title>
            <Reference>
                <Citation>Kuro-o M, Moe OW. FGF23-alpha Klotho as a paradigm for a kidney-bone network. Bone. 2017;100:4-18.</Citation>
            </Reference>
            <Reference>
                <Citation>Krajisnik T, Bjorklund P, Marsell R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007;195:125-131.</Citation>
            </Reference>
            <Reference>
                <Citation>Isakova T., Cai X., Lee J., et al. Longitudinal FGF23 trajectories and mortality in patients with CKD. J Am Soc Nephrol. 2018;29:579-590.</Citation>
            </Reference>
            <Reference>
                <Citation>Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370-1378.</Citation>
            </Reference>
            <Reference>
                <Citation>Graciolli FG, Neves KR, Barreto F, et al. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. Kidney Int. 2017;91:1436-1446.</Citation>
            </Reference>
            <Reference>
                <Citation>Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299:F882-F889.</Citation>
            </Reference>
            <Reference>
                <Citation>Masuyama R, Stockmans I, Torrekens S, et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest. 2006;116:3150-3159.</Citation>
            </Reference>
            <Reference>
                <Citation>David V, Martin A, Isakova T, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016;89:135-146.</Citation>
            </Reference>
            <Reference>
                <Citation>Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR, et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol. 2012;23:1190-1197.</Citation>
            </Reference>
            <Reference>
                <Citation>Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocr Metab. 2005;90:1519-1524.</Citation>
            </Reference>
            <Reference>
                <Citation>Feger M, Hase P, Zhang BB, et al. The production of fibroblast growth factor 23 is controlled by TGF ss 2. Sci Rep. 2017;7:4982.</Citation>
            </Reference>
            <Reference>
                <Citation>Meir T, Durlacher K, Pan Z, et al. Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int. 2014;86:1106-1115.</Citation>
            </Reference>
            <Reference>
                <Citation>Hocher B, Oberthur D, Slowinski T, et al. Modeling of oxidized PTH (oxPTH) and non-oxidized PTH (n-oxPTH) receptor binding and relationship of oxidized to non-oxidized PTH in children with chronic renal failure, adult patients on hemodialysis and kidney transplant recipients. Kidney Blood Press Res. 2013;37:240-251.</Citation>
            </Reference>
            <Reference>
                <Citation>Ursem SR, Vervloet MG, Hillebrand JJG, de Jongh RT, Heijboer AC. Oxidation of PTH: in vivo feature or effect of preanalytical conditions? Clin Chem Lab Med. 2018;56:249-255.</Citation>
            </Reference>
            <Reference>
                <Citation>Hocher B, Armbruster FP, Stoeva S, et al. Measuring parathyroid hormone (PTH) in patients with oxidative stress-do we need a fourth generation parathyroid hormone assay? PLoS One. 2012;7:e40242.</Citation>
            </Reference>
            <Reference>
                <Citation>Panah F, Ghorbanihaghjo A, Argani H, Zarmehri MA, Ahmad SNS. Ischemic acute kidney injury and klotho in renal transplantation. Clin Biochem. 2018;55:3-8.</Citation>
            </Reference>
            <Reference>
                <Citation>Querfeld U, Anarat A, Bayazit AK, et al. The Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study: objectives, design, and methodology. Clin J Am Soc Nephrol. 2010;5:1642-1648.</Citation>
            </Reference>
            <Reference>
                <Citation>Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629-637.</Citation>
            </Reference>
            <Reference>
                <Citation>BÃ¤r L, Hase P, FÃ¶ller M. PKC regulates the production of fibroblast growth factor 23 (FGF23). PLOS ONE. 2019:14(3):e0211309. http://dx.doi.org/10.1371/journal.pone.0211309.</Citation>
            </Reference>
            <Reference>
                <Citation>Lowik CW, van der Pluijm G, Bloys H, et al. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun. 1989;162:1546-1552.</Citation>
            </Reference>
            <Reference>
                <Citation>Greenfield EM, Gornik SA, Horowitz MC, Donahue HJ, Shaw SM. Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res. 1993;8:1163-1171.</Citation>
            </Reference>
            <Reference>
                <Citation>Sakagami Y, Girasole G, Yu XP, Boswell HS, Manolagas SC. Stimulation of interleukin-6 production by either calcitonin gene-related peptide or parathyroid hormone in two phenotypically distinct bone marrow-derived murine stromal cell lines. J Bone Miner Res. 1993;8:811-816.</Citation>
            </Reference>
            <Reference>
                <Citation>Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005;37:148-158.</Citation>
            </Reference>
            <Reference>
                <Citation>Rhee Y, Allen MR, Condon K, et al. PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res. 2011;26:1035-1046.</Citation>
            </Reference>
            <Reference>
                <Citation>Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. 2010;25:178-189.</Citation>
            </Reference>
            <Reference>
                <Citation>Yang H, Dong J, Xiong W, Fang Z, Guan H, Li F. N-cadherin restrains PTH repressive effects on sclerostin/SOST by regulating LRP6-PTH1R interaction. Ann N Y Acad Sci. 2016;1385:41-52.</Citation>
            </Reference>
            <Reference>
                <Citation>Doyon A, Fischer D-C, Bayazit AK, et al. Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease. PLoS One. 2015;10:e0113482.</Citation>
            </Reference>
            <Reference>
                <Citation>Tepel M, Armbruster FP, Gron HJ, et al. Nonoxidized, biologically active parathyroid hormone determines mortality in hemodialysis patients. J Clin Endocrinol Metab. 2013;98:4744-4751.</Citation>
            </Reference>
            <Reference>
                <Citation>Cheloha RW, Gellman SH, Vilardaga JP, Gardella TJ. PTH receptor-1 signalling-mechanistic insights and therapeutic prospects. Nat Rev Endocrinol. 2015;11:712-724.</Citation>
            </Reference>
            <Reference>
                <Citation>Zull JE, Smith SK, Wiltshire R. Effect of methionine oxidation and deletion of amino-terminal residues on the conformation of parathyroid hormone. Circular dichroism studies. J Biol Chem. 1990;265:5671-5676.</Citation>
            </Reference>
            <Reference>
                <Citation>Frelinger AL 3rd, Zull JE. The role of the methionine residues in the structure and function of parathyroid hormone. Arch Biochem Biophys. 1986;244:641-649.</Citation>
            </Reference>
            <Reference>
                <Citation>Lopez I, Rodriguez-Ortiz ME, Almaden Y, et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int. 2011;80:475-482.</Citation>
            </Reference>
            <Reference>
                <Citation>Liu SG, Tang W, Zhou JP, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17:1305-1315.</Citation>
            </Reference>
            <Reference>
                <Citation>Saji F, Shiizaki K, Shimada S, et al. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol. 2009;111:59-66.</Citation>
            </Reference>
            <Reference>
                <Citation>Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology. 2009;150:4835-4845.</Citation>
            </Reference>
            <Reference>
                <Citation>Burnett-Bowie SAM, Henao MP, Dere ME, Lee H, Leder BZ. Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res. 2009;24:1681-1685.</Citation>
            </Reference>
            <Reference>
                <Citation>Gutierrez OM, Smith KT, Barchi-Chung A, Patel NM, Isakova T, Wolf M. (1-34) parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers. Clin J Am Soc Nephro. 2012;7:139-145.</Citation>
            </Reference>
            <Reference>
                <Citation>Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010;21:1427-1435.</Citation>
            </Reference>
            <Reference>
                <Citation>Xu G, Luo K, Liu H, Huang T, Fang X, Tu W. The progress of inflammation and oxidative stress in patients with chronic kidney disease. Ren Fail. 2015;37:45-49.</Citation>
            </Reference>
            <Reference>
                <Citation>Lang F, Leibrock C, Pandyra AA, Stournaras C, Wagner CA, Foller M. Phosphate homeostasis, inflammation and the regulation of FGF-23. Kidney Blood Press Res. 2018;43:1742-1748.</Citation>
            </Reference>
            <Reference>
                <Citation>Ursem SR, Francic V, Keppel M, et al. The effect of vitamin D supplementation on plasma non-oxidised PTH in a randomised clinical trial. Endocr Connect. 2019;8(5):518-527.</Citation>
            </Reference>
            <Reference>
                <Citation>Hocher B, Zeng SF. Need for better PTH assays for clinical research and patient treatment. Clin Chem Lab Med. 2018;56:183-185.</Citation>
            </Reference>
            <Reference>
                <Citation>Lu YP, Zeng S, Chu C, et al. Non-oxidized PTH (n-oxPTH) is associated with graft loss in kidney transplant recipients. Clin Chim Acta. 2020;508:92-97.</Citation>
            </Reference>
            <Reference>
                <Citation>Cavalier E, Lukas P, Warling X, Moonen M, Smelten N, Delanaye P. The percentage of non-oxidized PTH concentration remains stable over a period of 1 year in hemodialyzed patients. Clin Chim Acta. 2020;506:107-109.</Citation>
            </Reference>
            <Reference>
                <Citation>Ursem SR, Vervloet MG, de Jongh RT, Heijboer AC. Oxidation of parathyroid hormone. Clin Chim Acta. 2020;506:84-91.</Citation>
            </Reference>
            <Reference>
                <Citation>Ursem S, Francic V, Keppel M, et al. The effect of vitamin D supplementation on plasma non-oxidised PTH in a randomised clinical trial. Endocr Connect. 2019;8:518-527.</Citation>
            </Reference>
            <Reference>
                <Citation>van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341-1352.</Citation>
            </Reference>
            <Reference>
                <Citation>Hayek SS, Sever S, Ko YA, et al. Soluble urokinase receptor and chronic kidney disease. New Engl J Med. 2015;373:1916-1925.</Citation>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>